Brolucizumab (Beovu, Novartis, Basel, Switzerland) was recently approved by the US FDA in October 2019 for the treatment of neovascular age-related macular degeneration (n-AMD). It is a single-chain antibody fragment (scFv), the smallest functional subunit of an antibody molecule, approved for the first time across all fields of medicine [1, 2].

Brolucizumab was approved on the basis of the pivotal phase 3 clinical trial results of the HAWK and HARRIER studies. Approximately 90% of the uveitis and iritis cases were mild to moderate, which were treated with a course of topical corticosteroids/antibiotics and most resolved with no sequelae [3]. Two of the 8 cases of uveitis were reported as a serious adverse event (SAE) in the 6 mg brolucizumab group, compared to 0 cases in the aflibercept group of HAWK trial, HARRIER had three incidences of uveitis, all reported as SAE. No case of reported iritis was categorized as SAE. One case of retinal artery thrombosis was noted in each of the trials (HAWK and HARRIER) with 6 mg of brolucizumab [3].

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD